SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Grady D,Gebretsadik T,Kerlikowske K,Ernster V,Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995; 85: 304313.
  • 2
    McKinney KA,Thompson W. A practical guide to prescribing hormone replacement therapy. Drugs. 1998; 56: 4957.
  • 3
    McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med. 1999; 131: 605616.
  • 4
    Gambrell RDJr,Massey FM,Castaneda TA, et al. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol. 1980; 55: 732738.
  • 5
    Whitehead MI,Townsend PT,Pryse-Davies J,Ryder TA,King RJ. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med. 1981; 305: 1599605.
  • 6
    [No authors listed.] Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1996; 275: 370375.
  • 7
    Pike MC,Peters RK,Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997; 89: 11101116.
  • 8
    Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med. 2005; 118: 6473.
  • 9
    Hill DA,Weiss NS,Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol. 2000; 183: 14561461.
  • 10
    Weiderpass E,Adami HO,Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999; 91: 11311137.
  • 11
    Beral V,Bull D,Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005; 365: 15431551.
  • 12
    Strom BL,Schinnar R,Weber AL, et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol. 2006; 164: 775786.
  • 13
    Newcomb PA,Trentham-Dietz A. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control. 2003; 14: 195201.
  • 14
    Lacey JVJr,Brinton LA,Lubin JH, et al. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005; 14: 17241731.
  • 15
    Jain MG,Rohan TE,Howe GR. Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol. 2000; 53: 385391.
  • 16
    Schatzkin A,Subar AF,Thompson FE, et al. Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol. 2001; 154: 11191125.
  • 17
    Michaud DS,Midthune D,Hermansen S, et al. Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Regist Manage. 2005; 32: 7075.
  • 18
    Gail MH,Lubin JH,Rubinstein LV. Likelihood calculations for matched case-control studies and survival studies with tied death times. Biometrika. 1981; 68: 703707.
  • 19
    Sherman ME,Carreon JD,Lacey JVJr,Devesa SS. Impact of hysterectomy on endometrial carcinoma rates in the United States. J Natl Cancer Inst. 2005; 97: 17001702.
  • 20
    Keshavarz H,Hillis SD,Kieke BA,Marchbanks PA. Hysterectomy Surveillance—United States, 1994–1999. MMWR. 2002; 51: 18.
  • 21
    Voigt LF,Weiss NS,Chu J, et al. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet. 1991; 338: 274277.
  • 22
    Beresford SA,Weiss NS,Voigt LF,McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 1997; 349: 458461.
  • 23
    Reed SD,Voigt LF,Beresford SA, et al. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol. 2004; 191: 11461151.
  • 24
    Hersh AL,Stefanick ML,Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004; 291: 4753.
  • 25
    Ettinger B,Pressman A,Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause. 1999; 6: 282289.
  • 26
    Anderson GL,Judd HL,Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003; 290: 17391748.
  • 27
    Kurman RJ,Kaminski PF,Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985; 56: 403412.